How many clinical trials are studying Cabozantinib?

6 recruiting trials in our tracked data involve Cabozantinib.

What conditions is Cabozantinib being studied for?

In our tracked recruiting trials, Cabozantinib is being studied in trials for Lung cancer, Colorectal Cancer, Autoimmune Disease.

Cabozantinib: clinical trials recruiting now

Q: Is Cabozantinib FDA-approved?

Yes. According to the FDA drug label available through openFDA, Cabozantinib is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Cabozantinib appears in the FDA drug-label database. Marketed as COMETRIQ.

FDA-approved use

COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 )

FDA label via openFDA

Phase breakdown

Phase 1 4 Phase 2 3

Conditions being studied

Condition	Trials
Lung cancer · Cabozantinib for Lung cancer	3
Colorectal Cancer	2
Autoimmune Disease	1
Clear Cell Renal Cell Carcinoma (ccRCC)	1
Colorectal Cancer (CRC)	1
Crohn Disease	1
Crohn's disease	1
Dermatomyositis	1
Esophageal Adenocarcinoma	1
Gastric Cancer	1
Hematopoietic and Lymphoid Cell Neoplasm	1
Hepatocellular Carcinoma	1
Inflammatory Bowel Disease	1
Lupus	1
Malignant Solid Neoplasm	1

Recruiting trials involving Cabozantinib

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT05613413 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
NCT03539822 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
NCT01639508 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05613894 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 260 locations

Common questions

Is Cabozantinib FDA-approved?

Yes, marketed as COMETRIQ.

How many recruiting trials involve Cabozantinib?

6 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.